D-Amino Acids in Disease: When Mirror-Image Molecules Signal Something Wrong

D-amino acids and D-amino acid-containing peptides accumulate in diseases like Alzheimer's and cataracts, potentially serving as both biomarkers for diagnosis and targets for new therapies.

Abdulbagi, Mohamed et al.·Biomolecules·2021·n/aReview
RPEP-05252Reviewn/a2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
n/a
Sample
Not applicable (review of D-amino acids in human disease)
Participants
Not applicable (review of D-amino acids in human disease)

What This Study Found

D-amino acids and D-amino acid-containing peptides (DAACPs) have been found in patients with cataracts, Alzheimer's disease, and other conditions, where they may serve as disease biomarkers or therapeutic targets. The spontaneous conversion of L-amino acids to their D-form in long-lived proteins alters protein structure and function, potentially contributing to disease progression. Elevated free D-amino acid levels in certain diseases reflect altered metabolism and may provide diagnostic value. Advances in analytical techniques are improving our ability to detect and study these mirror-image molecules.

Key Numbers

DAACPs found in: cataracts, Alzheimer's disease, and other conditions · Free D-amino acids: altered levels in multiple diseases · Focus: L→D conversion in long-lived proteins

How They Did This

Literature review summarizing the occurrence of D-amino acids and DAACPs in disease, their molecular mechanisms of formation, links to disease development, and recent advances in analytical detection techniques.

Why This Research Matters

Most biology assumes all amino acids are L-form, but D-amino acids accumulate naturally in aging tissues and diseased proteins. This review highlights an underappreciated dimension of peptide biochemistry: the spontaneous flip from L to D in proteins like beta-amyloid (Alzheimer's) and lens crystallins (cataracts) may actively drive disease rather than being a passive consequence. Understanding this process could reveal new diagnostic biomarkers and drug targets.

The Bigger Picture

The presence of D-amino acids in disease adds a layer of complexity to peptide and protein biology that's often overlooked. In Alzheimer's disease, the discovery of D-aspartate and D-serine residues in amyloid-beta peptides suggests that age-related amino acid racemization could make these peptides more toxic or resistant to clearance. This intersects with the broader goal of understanding why protein aggregation diseases increase with age — the gradual accumulation of D-amino acid modifications may be one answer.

What This Study Doesn't Tell Us

Narrative review without systematic methodology. The field of D-amino acid biology in disease is still developing, with many findings correlational rather than causal. Analytical challenges in detecting D-amino acids have historically limited research in this area.

Questions This Raises

  • ?Could measuring D-amino acid levels in blood or cerebrospinal fluid provide early diagnostic biomarkers for Alzheimer's disease?
  • ?Do D-amino acid-containing amyloid-beta peptides resist degradation differently than their all-L counterparts, contributing to plaque persistence?
  • ?Can enzymes or drugs that specifically target D-amino acid-modified proteins be developed as therapies?

Trust & Context

Key Stat:
Mirror-image amino acids found in multiple diseases D-amino acid-containing peptides have been isolated from patients with cataracts, Alzheimer's disease, and other conditions where long-lived proteins undergo age-related modifications
Evidence Grade:
This is a narrative review summarizing an emerging field. The individual studies cited range from analytical chemistry to clinical observations. The evidence for D-amino acids as biomarkers is growing but not yet clinically validated. Evidence grading doesn't directly apply to methods reviews.
Study Age:
Published in 2021, this review captures a growing field enabled by improvements in chiral analytical techniques. Research on D-amino acids in disease continues to expand as detection methods improve.
Original Title:
D-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets?
Published In:
Biomolecules, 11(11) (2021)
Database ID:
RPEP-05252

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What's the difference between L and D amino acids?

L and D amino acids are mirror images of each other, like left and right hands. Life almost exclusively uses L-amino acids to build proteins. D-amino acids are the same chemical formula but flipped in 3D space. When an L-amino acid spontaneously converts to D in a protein, it can change the protein's shape and function, potentially contributing to disease.

How do D-amino acids end up in diseased tissues?

In long-lived proteins that don't get replaced often (like eye lens proteins or brain amyloid deposits), L-amino acids can spontaneously convert to D-form over years or decades through a process called racemization. This is essentially a molecular aging process. The accumulation of these flipped amino acids may contribute to protein malfunction and disease.

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-05252·https://rethinkpeptides.com/research/RPEP-05252

APA

Abdulbagi, Mohamed; Wang, Liya; Siddig, Orwa; Di, Bin; Li, Bo. (2021). D-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets?. Biomolecules, 11(11). https://doi.org/10.3390/biom11111716

MLA

Abdulbagi, Mohamed, et al. "D-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets?." Biomolecules, 2021. https://doi.org/10.3390/biom11111716

RethinkPeptides

RethinkPeptides Research Database. "D-Amino Acids and D-Amino Acid-Containing Peptides: Potentia..." RPEP-05252. Retrieved from https://rethinkpeptides.com/research/abdulbagi-2021-damino-acids-and-damino

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.